Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marshall Edwards, an oncology company, has received an investigative new drug approval from the FDA to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine.
Subscribe to our email newsletter
This approval will enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.
Triphendiol (NV-196) is an investigational drug in the Marshall Edwards oncology drug pipeline, currently being developed as an orally-delivered chemosensitizing agent, intended for use in conjunction with standard chemotoxic anticancer drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and melanoma.